# Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

> **NCT02256488** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 1561 (actual)

## Conditions studied

- Prophylaxis: Influenza

## Interventions

- **BIOLOGICAL:** TIVc_LOT A
- **BIOLOGICAL:** TIVc_LOT B
- **BIOLOGICAL:** TIVc_LOT C
- **BIOLOGICAL:** TIVf

## Key facts

- **NCT ID:** NCT02256488
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 1561 (ACTUAL)
- **Last updated:** 2019-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256488, "Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02256488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*